Inavolisib combination reduces PFS advanced HR+, HER2- breast cancer with PIK3CA mutation

The Fund for Science and Technology awards $500 million to four grantees in Seattle for immunotherapy research, climate science

The Fund for Science and Technology announced an inaugural suite of grants and its plan to fund at least $500 million over the next four years to support transformational science and technology for people and the planet.

September 19, 2025

Vol.51 No.34

Clinical Roundup

How AI will transform mental health support for breast cancer patients, narrative review paper details

Researchers from UVA Cancer Center, the University of Virginia School of Medicine, and Inova Peterson Life with Cancer detail the many ways artificial intelligence could help ensure patients receive the support they need.

September 19, 2025

Vol.51 No.34

In Brief

VCU Massey, MD Anderson researchers awarded $7.3M grant to launch breast cancer clinical trial

Venkata Lokesh BattulaClinton YamA multidisciplinary team of researchers at VCU Massey Comprehensive Cancer Center and MD Anderson Cancer Center has been awarded a $7.3 million grant from the U.S. Department of Defense to fund a novel clinical trial targeting one of the most aggressive and hard-to-treat forms of breast cancer: metastatic triple-negative breast cancer.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Pre- and post-surgery immunotherapy combination shows promise for mesothelioma, Johns Hopkins-led study shows

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg Kimmel Institute for Cancer Immunotherapy.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Cancer Center at Illinois researcher unveils targeting technology for cancer immunotherapy

Hua Wang, an assistant professor in the departments of Material Science & Engineering, Bioengineering, Materials Research Lab, and Biomedical and Translational Sciences, finetunes an important technology in biomaterial chemistry at the Cancer Center at Illinois, which could potentially make way for more potent cancer immunotherapies.

September 12, 2025

Vol.51 No.33

Clinical Roundup

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

The MammaPrint, a gene expression profiling test, predicts the benefit of chemotherapy for patients with hormone receptor-positive, HER2-negative early-stage breast cancer, according to findings published in JNCI Cancer Spectrum.

September 05, 2025

Vol.51 No.32

Inavolisib combination reduces PFS advanced HR+, HER2- breast cancer with PIK3CA mutation

YOU MAY BE INTERESTED IN

The Fund for Science and Technology awards $500 million to four grantees in Seattle for immunotherapy research, climate science

How AI will transform mental health support for breast cancer patients, narrative review paper details

VCU Massey, MD Anderson researchers awarded $7.3M grant to launch breast cancer clinical trial

Pre- and post-surgery immunotherapy combination shows promise for mesothelioma, Johns Hopkins-led study shows

Cancer Center at Illinois researcher unveils targeting technology for cancer immunotherapy

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

Renew today!

Subscriber content

Never miss an issue!

Login